Three things to know:
1. The funding was provided by the Peer Reviewed Orthopedic Research Program of the U.S. Department of Defense.
2. The phase 1/2 clinical trial will study HST-003, a biologic product that regenerates tissue, in a microfracture procedure in 15 patients with focal cartilage defects in the knee.
3. OasisMD in San Diego, The Steadman Clinic in Vail, Colo., and Walter Reed Medical Center in Bethesda, Md., will serve as clinical sites for the trial.
More articles on biologics:
8 spine, orthopedic expansions costing $120M+
5 spine surgeons pioneering novel procedures — Drs. Justin Brown, Dror Paley & more
How Medtronic, Stryker, Johnson & Johnson’s shares performed this week
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
